focus -WSS

focus

author：entertainment 2025-09-30 00:35:44 - browse：3425

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： AstraZeneca chief proposes a novel edit to the drug pricing bill

WSS

Creating egg and sperm cells from stem cells raises ethical issues

How to protect patients from sexual assault

What American doctors can learn from their Israeli counterparts

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Colonoscopy prep: Liquid

entertainment

focus

entertainment

23andMe had bad news about my health. I wish a person had delivered it

Positive childhood experiences can help future health

Malaria cases in Florida and Texas: Here’s what you need to know

Neuroscience’s long legacy of racism

Cancer drug shortages should be causing more outrage

Virtual Event: March of the Biosimilars

Trump demands the U.S. pay no more for drugs than other countries … again

A rare thyroid diagnosis led to unexpected, all

At least 13 dead in Texas as scorching temps continue

Stem cell treatment guidelines are released by FDA

focus

Snackable artificial intelligence, expert AI, and the pharma industry

Future doctors should be trained to promote social change

NIH nominee Bertagnolli will get October confirmation hearing

Neuroscience’s long legacy of racism

The (many) problems with a new study criticizing cancer screening

How to fix cancer clinical trials' diversity problem

focus

entertainment

knowledge

focus